Treatment of advanced ovarian and endometrial cancer in the phase I setting: A single center experience.

e13509 Background: Targeted therapy of recurrent/metastatic ovarian and endometrial cancer remains of great interest but has not been established as standard of care. We analyzed a series of patients treated with targeted anti-cancer agents alone (group S) or in conjunction with cytotoxic therapies (group C) in the phase I setting to determine which approach would yield greater potential for benefit. Methods: We reviewed the records of 46 patients with recurrent or metastatic ovarian and endometrial cancer, who were previously treated with paclitaxel and carboplatin, and were enrolled onto a series of phase I trials. Treatment outcomes were evaluated and were correlated with treatment modalities. Results: 46 patients were enrolled onto 40 different trials, with a total of 72 enrollments; 65 of the enrollments having disease assessment, of which 56 had measurable disease. The confirmed ORR (overall response rate) of the 65 enrollments was 7.7% and mTTF (median time to treatment failure) was 2.9 months (95%...